Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study-Reference-Cited by-同舟云学术

Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study

Published:2022-04 Issue:2 Volume:7 Page:100458
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Lasagna A.,Bergami F.,Lilleri D.,Percivalle E.,Quaccini M.,Alessio N.,Comolli G.,Sarasini A.,Sammartino J.C.,Ferrari A.,Arena F.,Secondino S.,Cicognini D.,Schiavo R.,Lo Cascio G.,Cavanna L.,Baldanti F.,Pedrazzoli P.,Cassaniti I.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference24 articles.

1. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine;Polack;N Engl J Med,2020

2. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months;Thomas;N Engl J Med,2021

3. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China;Liang;Lancet Oncol,2020

4. Immunogenicity and risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection after coronavirus disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis;Becerril-Gaitan;Eur J Cancer,2022

5. A snapshot of the immunogenity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study;Lasagna;ESMO Open,2021

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term levels of protection of different types of immunity against the Omicron variant: a rapid literature review;Swiss Medical Weekly;2024-05-06

2. Response Rate of the Third and Fourth Doses of the BNT162b2 Vaccine Administered to Cancer Patients Undergoing Active Anti-Neoplastic Treatments;Diseases;2023-09-26

3. Immunogenicity and Safety of Vaccines against Coronavirus Disease in Actively Treated Patients with Solid Tumors: A Prospective Cohort Study;Cancer Research and Treatment;2023-07-15

4. Safety and immunogenicity of a third dose of mRNA‐1273 vaccine among cancer patients;Cancer Communications;2023-06-28

5. Longitudinal data on humoral response and neutralizing antibodies against SARS-CoV-2 Omicron BA.1 and subvariants BA.4/5 and BQ.1.1 after COVID-19 vaccination in cancer patients;Journal of Cancer Research and Clinical Oncology;2023-06-10